PMA device
Medtronic Altaviva System
Medtronic Neuromodulation · Stimulator, Tibial, Electrical, Implantable, For Urinary Incontinence (QPT, Class III) · First FDA decision Sep 18, 2025, newest Dec 19, 2025Overactive bladder and urinary incontinence
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "Medtronic Altaviva"
MAUDE reports
0
Brand "Medtronic Altaviva", since 2015
PubMed studies
0
Mentioning "Medtronic Altaviva"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Medtronic Altaviva System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Medtronic Altaviva SystemPMA supplement
P240011-S004 · Decided Dec 19, 2025 · 28 days after receipt · Normal 180 Day Track No User Fee
Device type: Stimulator, tibial, electrical, implantable, for urinary incontinence (QPT) · GI, Urology & Nephrology
P240011 · Decided Sep 18, 2025 · 532 days after receipt
Device type: Stimulator, tibial, electrical, implantable, for urinary incontinence (QPT) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Pelvic Floor Electrical Stimulation for Urinary IncontinenceNational analysisReview closedCAG-00021NUpdated Sep 15, 2026
- Non-Implantable Pelvic Floor Electrical StimulatorNational determinationOn the books230.8Updated Aug 17, 2023
- Sacral Nerve Stimulation for Urge Urinary IncontinenceNational analysisReview closedCAG-00058NUpdated Sep 15, 2026
- Home Biofeedback For Urinary IncontinenceNational analysisReview closedCAG-00118NUpdated Sep 14, 2026
- Biofeedback for Urinary IncontinenceNational analysisReview closedCAG-00020NUpdated Sep 14, 2026
- Sacral Nerve Stimulation For Urinary IncontinenceNational determinationOn the books230.18Updated Dec 8, 2025
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Medtronic Altaviva", any status and sponsor, newest update first.
No registered device study names "Medtronic Altaviva".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Medtronic Altaviva", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QPT
81 reports: 2 malfunction, 77 injury, 1 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Medtronic Altaviva"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code QPT.
- eCoin Peripheral NeurostimulatorBoston Scientific Corporation · PMA 2026
- AltavivaMedtronic Neuromodulation · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.